Evolocumab (Repatha)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Evolocumab (Repatha) 140 mg/mL, prefilled syringea and autoinjector, subcutaneous injection 120 mg/mL, automated mini-doser with prefilled cartridge, subcutaneous injection. Indication: Evolocumab is indicated for the reduction of elevated low-density-lipoprotein cholesterol (LDL-C) in adult patients with primary hyperlipidemia (including heterozygous familial hypercholesterolemia [HeFH] and atherosclerotic cardiovascular disease [ASCVD]): as an adjunct to diet and statin therapy, with or without other lipid-lowering therapies, in patients who require additional lowering of LDL-C as an adjunct to diet, alone or in combination with nonstatin lipid-lowering therapies, in patients for whom a statin is contraindicated